Recombinant human growth hormone (rhGH) was introduced in 1985, replacing the previous, pituitary-derived option in many countries when the risk of contamination with the CJD prion was identified. At that time, specialists desired a patient registry to assess the safety and efficacy of the new treatment provided to patients in Europe and many other parts…